

Levodopa, Carbidopa and Entacapone (Stalevo®) (No. 85/03)
Orion Pharma (UK) Ltd

Product Update

12 January 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE: following an abbreviated submission

Accepted for use in NHSScotland.

Stalevo® for the treatment of patients with Parkinson's disease and end of dose motor fluctuations not stabilised on levodopa/dopa decarboxylase inhibitor treatment.

This combination preparation allows administration of a single tablet incorporating ingredients that are routinely combined for the indication described above. This may improve convenience to the patient. Depending on the doses and formulations being replaced, conversion to the combination may result in a modest increase in cost or (less commonly) a cost saving.

Professor D H Lawson
Chairman